# Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)

> **NCT02558972** · PHASE2 · TERMINATED · sponsor: **New York Medical College** · enrollment: 30 (estimated)

## Conditions studied

- Postural Tachycardia Syndrome (POTS)
- Vasovagal Syncope (VVS)
- Fainting

## Interventions

- **DRUG:** Northera (Droxidopa)
- **DRUG:** Placebo
- **DRUG:** Northera (Droxidopa)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02558972
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Could not recruit adequate numbers. Largely closed by COVID risk.
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02558972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02558972, "Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02558972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*